Related references
Note: Only part of the references are listed.CODEL: phase III study of RT, RT plus TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design
Kurt A. Jaeckle et al.
NEURO-ONCOLOGY (2021)
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Martin J. van den Bent et al.
LANCET ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)
Kihwan Hwang et al.
CANCER RESEARCH AND TREATMENT (2020)
Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma
William G. Breen et al.
NEURO-ONCOLOGY (2020)
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma
Antje Wick et al.
NEURO-ONCOLOGY (2020)
Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas
Amal Mosaab et al.
SCIENTIFIC REPORTS (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Carmen Balana et al.
NEURO-ONCOLOGY (2020)
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
Erica H. Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma
Alba A. Brandes et al.
ONCOLOGIST (2019)
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Ulrich Herrlinger et al.
LANCET (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2019)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi et al.
LANCET ONCOLOGY (2019)
A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma
Yoshitaka Narita et al.
NEURO-ONCOLOGY (2019)
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2018)
Bevacizumab plus nypofractionated raciotnerapy versus radiotherapy alone in elderly patients with glioblastoma: tie randomized, open-label, phase II ARTE trial
H-G. Wirsching et al.
ANNALS OF ONCOLOGY (2018)
Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology
Supriya G. Mohile et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)
Supriya Mallick et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients
Arif N. Ali et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma
Tanner M. Johanns et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
cIMPACT-NOW update 3: recommended diagnostic criteria for Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV
Daniel J. Brat et al.
ACTA NEUROPATHOLOGICA (2018)
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
Martin J. van den Bent et al.
LANCET ONCOLOGY (2018)
NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma
Mark R. Gilbert et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
Timothy Gilligan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
Betty R. Ferrell et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J. van den Bent et al.
LANCET (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma
Yushen Qian et al.
NEURO-ONCOLOGY (2017)
Reply to letter on results of NRG Oncology RTOG 9813
Susan M. Chang et al.
NEURO-ONCOLOGY (2017)
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James R. Perry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial
Annika Malmstrom et al.
ACTA ONCOLOGICA (2017)
Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations
David A. Solomon et al.
BRAIN PATHOLOGY (2016)
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial
Hendrikus J. Dubbink et al.
NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Ulrich Herrlinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Carmen Balana et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Shiao-Pei Weathers et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert et al.
LANCET ONCOLOGY (2016)
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Jan C. Buckner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
Alvin R. Cabrera et al.
PRACTICAL RADIATION ONCOLOGY (2016)
Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial
Ying Mao et al.
CHINESE MEDICAL JOURNAL (2015)
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
Manfred Westphal et al.
EUROPEAN JOURNAL OF CANCER (2015)
International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme
Wilson Roa et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Kathryn M. Field et al.
NEURO-ONCOLOGY (2015)
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
L. Burt Nabors et al.
NEURO-ONCOLOGY (2015)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Daniel J. Brat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study
Kenneth F. Hofland et al.
ACTA ONCOLOGICA (2014)
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFaEuro
B. Chauffert et al.
ANNALS OF ONCOLOGY (2014)
A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
Wolfgang Wick et al.
CLINICAL CANCER RESEARCH (2014)
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
Maria Teresa Solomon et al.
BMC CANCER (2013)
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States
Andrew Messali et al.
NEURO-ONCOLOGY (2013)
Enrollment of Patients With Lung and Colorectal Cancers Onto Clinical Trials
Mona N. Fouad et al.
JOURNAL OF ONCOLOGY PRACTICE (2013)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp et al.
EUROPEAN JOURNAL OF CANCER (2012)
Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802
Edward G. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability
Richard N. Shiffman et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Sonya Blesser Streeter et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
EFFECTS OF CONCURRENT TOPOTECAN AND RADIATION ON 6-MONTH PROGRESSION-FREE SURVIVAL IN THE PRIMARY TREATMENT OF GLIOBLASTOMA MULTIFORME
Gerhard G. Grabenbauer et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
Jennifer L. Clarke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Neal J. Meropol et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Randomized Study of Postoperative Radiotherapy and Simultaneous Temozolomide without Adjuvant Chemotherapy for Glioblastoma
Martin Kocher et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2008)
Radiotherapy for glioblastoma in the elderly
Florence Keime-Guibert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials
Jan C. Buckner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical trial accrual among new cancer patients at a community-based cancer center - A prospective study
RS Go et al.
CANCER (2006)
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults:: the EORTC 22845 randomised trial
MJ van den Bent et al.
LANCET (2005)
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
H Athanassiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol
L Souhami et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial
W Roa et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Prospective Randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study
E Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized trial of porcarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A medical research council trial
D Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)